Oral News and Research

RSS

Final Atlantis space trip may open new era of research into infectious diseases

On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.

7 Jul 2011

Women with sedentary lifestyle more likely to develop pulmonary embolism

Women who sit for long periods of time everyday are two to three times more likely to develop a life-threatening blood clot in their lungs than more active women, finds a study published on bmj.com today.

5 Jul 2011

'Genotype positive' individuals susceptible to increased periodontal tissue destruction after dental implants

The health of the surrounding tissue affects the success of a dental implant. Identifying and reducing risk factors is therefore a key step in the implant process. Now a combination of genes has been identified as a possible indicator of greater tissue destruction leading to negative outcomes for implants.

1 Jul 2011

JDR increases Five-Year Scientific Impact Factor

Today the International and American Associations for Dental Research announced that its Journal of Dental Research (JDR) has increased its Five-Year Scientific Impact Factor (SIF) from 4.195 to 4.389.

1 Jul 2011

Resveratrol may prevent negative effects of spaceflight and sedentary lifestyles

As strange as it sounds, a new research study published in the FASEB Journal (http://www.fasebj.org), suggests that the "healthy" ingredient in red wine, resveratrol, may prevent the negative effects that spaceflight and sedentary lifestyles have on people.

1 Jul 2011

Vitamin D-deficiency linked to deaths of famous musicians

Wolfgang Amadeus Mozart (27 January 1756 - 5 December 1791), suffered from many infectious illnesses including catarrh, fever, sore throat, and bad colds from 1762 to 1791, the year of his death at 35 years of age.

1 Jul 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

Vaccines may be given in food in the near future

Soon children could be vaccinated with bacteria mixed in milk and people in the developing world given unprecedented access to immunisations under a scheme proposed by an Australian Nobel laureate, Barry Marshall.

29 Jun 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011

Diet sodas and artificial sweeteners may not be healthy alternatives

In the constant battle to lose inches or at least stay the same, we reach for the diet soda. Two studies presented June 25 and 27 at the American Diabetes Association's Scientific Sessions in San Diego suggest this might be self-defeating behavior.

29 Jun 2011

Drug-resistant scarlet fever outbreak has infected nearly 550 people in Hong Kong

An outbreak of drug-resistant and particularly virulent strains of scarlet fever has infected nearly 550 people and killed two children in Hong Kong so far this year, about double the Chinese city's average annual total, the Associated Press reports.

29 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.

28 Jun 2011

Scientists discover how bacteria invade heart tissue and cause endocarditis

Scientists have discovered the tool that bacteria normally found in our mouths use to invade heart tissue, causing a dangerous and sometimes lethal infection of the heart known as endocarditis.

28 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

The Australian scientist who won a Nobel Prize for identifying a cancer-causing stomach bacterium, today said a clinical trial had shown that some strains of the bacteria (Helicobacter pylori or H. pylori) were safe and well tolerated in humans.

27 Jun 2011

Cardium to purchase Transdel's business assets

Cardium Therapeutics today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel (TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain.

27 Jun 2011

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.

27 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

Flamel, Digna Biotech enter joint development agreement for multiple products

Flamel Technologies SA and Digna Biotech SL today announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products.

27 Jun 2011

Oral News and Research

Final Atlantis space trip may open new era of research into infectious diseases

Women with sedentary lifestyle more likely to develop pulmonary embolism

'Genotype positive' individuals susceptible to increased periodontal tissue destruction after dental implants

JDR increases Five-Year Scientific Impact Factor

Resveratrol may prevent negative effects of spaceflight and sedentary lifestyles

Vitamin D-deficiency linked to deaths of famous musicians

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Vaccines may be given in food in the near future

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Diet sodas and artificial sweeteners may not be healthy alternatives

Drug-resistant scarlet fever outbreak has infected nearly 550 people in Hong Kong

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Scientists discover how bacteria invade heart tissue and cause endocarditis

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

Cardium to purchase Transdel's business assets

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

Flamel, Digna Biotech enter joint development agreement for multiple products

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News